Literature DB >> 15626881

Understanding erectile dysfunction medication preference studies.

John P Mulhall1.   

Abstract

PURPOSE OF REVIEW: The existence of three phosphodiesterase 5 inhibitors has resulted in an increase in the marketing of the drugs. This has led to a shift in focus from scientifically rigorous endpoints such as efficacy and adverse event profiles to patient preference. RECENT
FINDINGS: Although no consensus currently exists as to the correct methodology for preference studies, some basic guidelines should be adhered to, including: (1) the double-blinding of drug administration; (2) non-biased drug administration instructions; (3) an adequately conducted crossover study; (4) comparison of equivalent doses; (5) standardized preference assessment; (6) declaration of patient demographics; and (7) rigorous statistical analysis. These factors are discussed in the light of the three published preference studies.
SUMMARY: In the final analysis, it is unclear to this author how preference studies impact upon clinician decision-making when confronted by a patient with erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15626881     DOI: 10.1097/00042307-200411000-00013

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  4 in total

Review 1.  Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior.

Authors:  Hans Hedelin; Peter Ströberg
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.

Authors:  Wen-Jun Bai; Hong-Jun Li; Yu-Tian Dai; Xue-You He; Yi-Ran Huang; Ji-Hong Liu; Sebastian Sorsaburu; Chen Ji; Jian-Jun Jin; Xiao-Feng Wang
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

3.  A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.

Authors:  Wen-Jun Bai; Hong-Jun Li; Jian-Jun Jin; Wen-Ping Xu; Sorsaburu Sebastian; Xiao-Feng Wang
Journal:  Asian J Androl       Date:  2017 Jul-Aug       Impact factor: 3.285

4.  Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.

Authors:  Konstantinos Giannitsas; Angelis Konstantinopoulos; Christos Patsialas; Petros Perimenis
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.